- Acefylline
-
- $50.00
-
2026-07-27
- CAS:652-37-9
- Purity: 99.95%
- Supply Ability: 10g
|
| | Theophylline-7-acetic acid Basic information |
| Product Name: | Theophylline-7-acetic acid | | Synonyms: | THEOPHYLLINE-7-ACETIC ACID;THEOPHYLLINEACETIC ACID;(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid;7H-Purine-7-aceticacid, 1,2,3,6-tetrahydro-1,3-diMethyl-2,6-dioxo-;1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-purine-7-aceticaci;1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-aceticacid;7-(carboxymethyl)theophylline;7-theophyllinylaceticacid | | CAS: | 652-37-9 | | MF: | C9H10N4O4 | | MW: | 238.2 | | EINECS: | 211-490-2 | | Product Categories: | Pharmaceuticals;Organic acids;Bases & Related Reagents;Heterocycles;Intermediates & Fine Chemicals;Nucleotides | | Mol File: | 652-37-9.mol |  |
| | Theophylline-7-acetic acid Chemical Properties |
| Melting point | 270-272 °C | | Boiling point | 269-271 C | | density | 1+-.0.1 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Room Temperature | | solubility | DMSO (Slightly) | | form | Solid | | pka | 3.72±0.10(Predicted) | | color | White | | Merck | 14,24 | | BRN | 279221 | | Cosmetics Ingredients Functions | SKIN CONDITIONING | | LogP | -0.490 (est) | | CAS DataBase Reference | 652-37-9(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 2 | | RTECS | UO7451300 | | HS Code | 2939.59.0000 |
| | Theophylline-7-acetic acid Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | Bronchospasm;Adenosine receptor antagonist | | Definition | ChEBI: 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid is an oxopurine. | | Synthesis | General method: LiOH-H2O (1.5 eq.) was added in batches to a stirred solution of ester compounds 2a-2b (1.0 eq.) dissolved in THF (10 v/v) and H2O (10 v/v) at room temperature, and the reaction mixture was stirred continuously for 2 hr. The reaction progress was monitored by TLC. Upon completion of the reaction, THF was removed by concentration under reduced pressure, acidified to acidity with aqueous KHSO4, and subsequently extracted with a solvent mixture of 5% methanol and dichloromethane. The organic phases were combined, dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the target solid products 3a-3b.
4.2.3 Synthesis of 2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)acetic acid (3a): compound 2a (5 g, 18.78 mmol) was dissolved in 100 mL of THF:H2O (1:1) mixed solvent, LiOH-H2O (1.18 g, 28.18 mmol) was added, and the product was extracted as described in the The above general method was operated to give the white solid product 3a (4.1 g, 91% yield).1H NMR (400 MHz, DMSO-d6) δ: 13.27 (brs, 1H), 8.04 (s, 1H), 5.07 (s, 2H), 3.44 (s, 3H), 3.20 (s, 3H); m/z (ES)+: 239.04 [M +H]+. | | References | [1] European Journal of Medicinal Chemistry, 2016, vol. 123, p. 379 - 396
[2] MedChemComm, 2017, vol. 8, # 1, p. 176 - 183
[3] Ricerca Scientifica, 1952, vol. 22, p. 1596,1599
[4] Journal of Medicinal Chemistry, 1999, vol. 42, # 14, p. 2527 - 2534
[5] Heterocyclic Communications, 2015, vol. 21, # 1, p. 13 - 18 |
| | Theophylline-7-acetic acid Preparation Products And Raw materials |
| Raw materials | 6-amino-5-formamido-1,3-dimethyluracil-->7H-Purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-, ethyl ester-->Sodium chloroacetate-->Water-->Lithium hydroxide monohydrate-->Tetrahydrofuran | | Preparation Products | 2-(1,3-dimethyl-2,6-dioxo-purin-7-yl)acetic acid-->1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purine-7-acetyl chloride-->methyl (1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetate |
|